Treatment of oral mucosal manifestations of chronic graft-versus-host disease: dexamethasone vs. budesonide

Expert Opin Pharmacother. 2017 Feb;18(3):235-242. doi: 10.1080/14656566.2017.1282464. Epub 2017 Jan 25.

Abstract

The oral mucosa is commonly involved in chronic graft-versus-host disease (cGVHD). Oral mucosal cGVHD markedly affect individual's daily function and wellbeing. In some cases, it might become a life threating complication. Areas covered: This article describes the rationale for treatment, method of topical application in the oral cavity, evidence supporting the topical administration of dexamethasone and budesonide for oral cGVHD, and their adverse effects. Expert opinion: Evidence supports the use of topical dexamethasone and budesonide for treatment of oral cGVHD. Topical corticosteroid choice for oral cGVHD, takes into consideration the potency, bioavailability, preferred concentration, and possible adverse effects. Budesonide's pharmacological characteristics mark it as a preferable topical agent for oral cGVHD.

Keywords: Budesonide; chronic graft-versus-host disease; dexamethasone; hematopoietic stem cell transplantation; mucosa; oral; oral medicine; pain.

Publication types

  • Review

MeSH terms

  • Administration, Topical
  • Budesonide / administration & dosage
  • Budesonide / therapeutic use*
  • Chronic Disease
  • Dexamethasone / administration & dosage
  • Dexamethasone / therapeutic use*
  • Female
  • Glucocorticoids / administration & dosage
  • Glucocorticoids / therapeutic use*
  • Graft vs Host Disease / drug therapy*
  • Graft vs Host Disease / immunology
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Humans
  • Male
  • Mouth Mucosa / drug effects*
  • Mouth Mucosa / immunology

Substances

  • Glucocorticoids
  • Budesonide
  • Dexamethasone